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Advanced ovarian cancer displays functional intra-tumour heterogeneity 
which correlates to ex vivo drug sensitivity 
 






Introduction Epithelial ovarian cancer (EOC) is recognised to be heterogeneous but is currently 
treated with a single treatment strategy. Successful patient stratification of emerging chemotherapy 
agents is dependent upon the availability of reliable biomarkers indicative of the entire tumour.  
Aim To evaluate inter- and intra-tumour heterogeneity within a series of EOC using homologous 
recombination DNA repair (HR) status. 
Methods Primary cultures generated from ascites and solid tumour from multiple intra-abdominal 
sites were characterised by their morphology and expression of protein markers. Results were 
compared with FFPE tissue pathology.   
HR function was determined by quantification of nuclear Rad51 foci. Growth inhibition (SRB) assays 
were used to calculate the GI50 for cisplatin and rucaparib.  
Results Ascites with matched solid tumour were cultured from 25 patients.  
Concordance in functional HR status between ascites and solid tumour subcultures was seen in only 
13/25 (52%) patients. Heterogeneity in HR status was seen even in patients with homogeneous 
histological subtype. HR defective cultures were significantly more sensitive to cisplatin and 
rucaparib.  
Additionally inter- and intra-tumour heterogeneity was seen between the expression of epithelial 
and ovarian markers (EpCAM, cytokeratin, CA125, MOC-31 and vimentin). There was no relationship 
between heterogeneity of HR functional status and antigen expression.  
Conclusions Inter- and intra-tumour functional HR heterogeneity exists that cannot be detected 
using histological classification. This has implications for biomarker directed treatment.  
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The term ovarian cancer describes a set of distinct and heterogeneous diseases, all of which are 
currently treated with a single treatment regimen. Despite advances in surgery and the addition of 
taxane to platinum chemotherapy, the 5-year survival has remained low at 30-40%.  Improved 
outcomes will require the use of targeted agents and novel cytotoxic agents exploiting the molecular 
pathology of the tumour.  
Reliable molecular predictive biomarkers are still lacking for ovarian cancer.  The classification of 
epithelial ovarian cancer into histological types (high grade serous, endometrioid, clear cell, 
mucinous and low grade serous), associated with different driver mutations, is well established but 
more recent work has taken this further and subdivided high grade serous cancer using genomic [1], 
gene expression [2] and functional [1, 3] techniques.  This has generated at least four distinct gene 
expression subgroups [2, 4] with diverse prognostic behaviour. This approach however has not yet 
successfully identified a reliable gene signature capable of predicting actual response to cytotoxic 
agents. Subdivision into groups according to overall function of a DNA repair pathway (homologous 
recombination)  [3] is not related to histological subgroup and has potential to enable stratification 
of patients according to differences in their sensitivity to conventional and novel chemotherapy 
agents [5, 6]. 
To date, systemic treatment for epithelial ovarian cancer has been platinum based, irrespective of 
histological subtype or other biological markers. An increased understanding of the disease 
combined with the development of new, targeted, agents is changing this model and allowing the 
development of personalised medicine. However, effective delivery of novel agents and the correct 
selection of patients will require the use of accurate biomarkers capable of predicting response and 
there is great interest in developing these from both academia [7] and industry [8]. Ovarian cancer 
typically presents at a disseminated stage with multiple sites of disease within the peritoneal cavity 
and elsewhere. Unless tumours are homogeneous it is likely that biopsies from a single site of a 
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tumour may not be representative of the rest of the tumour and therefore be unable to predict 
response accurately. In particular, most biopsies used for clinical diagnosis are taken from the 
omentum under radiological guidance. It is rare for disease on the diaphragm or nodal disease to be 
sampled. Given that there may be biological differences between disease which disseminates within 
the peritoneal cavity, through direct spread, compared to disease that disseminates by a classical 
process using lymphatic or haematogenous spread [9] it is likely that there could be a systematic 
bias in reporting of biopsies. There is no published evidence demonstrating radiological variable 
response to chemotherapy within an individual patient across different tumour sites but this is likely 
to reflect a lack of studies. RECIST criteria take into account measured response in both target and 
non-target lesions giving an overall response rather than documentation of individual lesions by 
anatomical site.  As molecular data taken from biopsies start to be used to direct therapy both in 
clinical trials and in clinical practice, knowledge of heterogeneity between intra-abdominal sites 
becomes increasingly important.  Genetic intra-tumoural heterogeneity has been demonstrated but 
the question of functional heterogeneity and subsequent response to therapy has not been 
addressed in any prospective study. 
 
Intra-tumoural heterogeneity can currently be assessed using morphological classification or analysis 
of genetic mutations. The histological subtypes of epithelial ovarian cancer have distinct and 
different pathogenetic processes [10] with variable response to therapy but true morphological 
heterogeneity is relatively rare in ovarian cancer and it has been suggested that this is 
overdiagnosed [11]. This suggests that histology alone is not sensitive enough to detect changes in 
underlying tumour biology. . There is general consensus that most cases of ovarian cancer are 
monoclonal in origin with a high degree of genomic parsimony but significant heterogeneity exists 
within microsatellites and SNPs [12] and copy number changes and driver mutation status [13] from 
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anatomically distinct regions.  This does not appear to translate into a significant degree of 
heterogeneity in terms of gene expression [14]. 
Other possible mechanisms of heterogeneity, including epigenetic changes in methylation, which is 
known to be important in determining functional status of the tumour, have not been studied. 
There is therefore evidence that significant ITH is likely to exist but how this knowledge can be 
employed to provide prediction to treatment is less clear. 
Cancers develop heterogeneity as a result of a process of somatic evolution but many of the 
mutations that occur have no functional effect and are termed passenger mutations. It may be more 
clinically relevant to examine the functional effects of heterogeneity rather than just relying on 
genomic variation. For this reason we have developed functional assays for homologous 
recombination DNA repair (HR) [15, 16].  
The aim of this study was to evaluate the extent of intra- and inter-tumour heterogeneity within a 
series of ovarian cancers using homologous recombination DNA repair status as a biomarker, and 
consider the potential impact of heterogeneity upon response to treatment and the subsequent 
management of such disease.  
 
Materials and Methods 
Reagents 
Rucaparib was a gift from Clovis (Boulder, USA) and is a potent inhibitor of PARP-1 and -2 proteins 
(Ki <5 nM). Rucaparib was dissolved in DMSO to give a stock solution of 10 mM, which was stored at 
−20 °C for in vitro studies. Cisplatin (Alexis Biochemicals, California USA) is a potent antineoplastic 
drug which forms inter- and intra-strand DNA adducts. Cisplatin was dissolved in water to give stock 
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solution of 2 mM, which was stored at -20 °C. All other chemicals and tissue culture reagents were 
from Sigma-aldrich (Sigma-aldrich, UK), unless otherwise stated.  
Cell Culture 
Sample collection 
Ethical approval was granted (12/NW/0202) for the collection of ascites and solid tissue from 
consented patients undergoing surgery for ovarian cancer at the Queen Elizabeth Hospital, 
Gateshead, UK. Samples were collected between 02/2012 and 08/2013 from patients recruited 
with radiological evidence of pelvic masses suspicious for or confirmed to be an ovarian 
malignancy.  Clinical details were recorded and specimens registered and handled in accordance 
with the Human Tissue Act. Samples were assigned a PCO (Primary Culture Ovary) reference number 
to retain anonymity. All samples were handled separately with their own reagents to prevent cross-
contamination.  
 
Sample transport and preparation 
Ascitic fluid was aspirated directly from the patient into a sterile suction bottle. Solid tumour 
specimens of approximately 1 cm3 were excised from surgical specimens and from any areas of 
irresectable tumour intra-operatively. The sample site was carefully documented and the solid 
tumour was placed into a sterile universal containing culture medium (RPMI 1640 medium 
supplemented with 10% FCS, 20mM L-glutamine and 1% penicillin and streptomycin) pre-warmed to 
37C. Samples were transported from the hospital to the lab immediately in compliance with UK 
Category B regulations UN3373.  
Ascitic cell culture 
Cell culture was performed using an aseptic technique in a containment level II laminar flow 
microbiological safety cabinet, as previously described [17]. Briefly, 20 ml of ascitic fluid was added 
7 
 
to 20 ml of warmed culture medium (RPMI 1640 medium supplemented with 10% FCS, 20 mM L-
glutamine and 1% penicillin and streptomycin)  in T75 flasks (Corning, NY) and incubated at 37°C, 5% 
CO2, 95% humidified air. The medium was aspirated and 13 ml of warmed fresh medium was 
replaced on day 3 to 5. When confluence was approached cells were passaged, frozen and thawed 
as previously described [18].  
Primary culture from solid tumour 
Solid culture was performed using techniques previously described [17]. Briefly, 1 cm3 solid tumour 
collected from intra-abdominal sites during cytoreductive surgery and transported to the lab in 
warmed culture media was dissected into ~3 mm3 pieces and incubated with collagenase/dispase 
(Roche, UK) solution (1 mg/ml in full medium) for 2 hours at 37C on an orbital shaker (IKA-Vibrax-
VKR) at 2xg. The cell suspension was transferred to a universal container, centrifuged at 400xg for 5 
minutes, PBS washed, re-suspended in full medium and placed in a T25 flask for 30 minutes to allow 
fibroblast seeding. The remaining cell suspension containing an epithelial rich cell suspension was 
transferred into a T25 flask for on-going cell culture, in RPMI medium containing 10% (v/v) fetal calf 
serum. When approaching confluence cells were trypsinised, PBS washed and seeded onto sterile 
coverslips for characterisation and Rad51 HR assay and plated for cell proliferation assays described 
below. 
Characterisation 
A single marker is insufficient to reliably differentiate epithelial ovarian cancer cells from all 
histological subtypes from other cell types sampled from solid tissue or ascites. A characterisation 
panel consisting of cell culture morphology, immunofluorescent staining of fixed cells, as well as 
standard pathological and immunohistochemistry examination of paired FFPE samples was 




Morphological features of cells in culture were studied under an Olympus CK40 inverted microscope 
at 20X magnification and images were captured using VisiCam® software (VWR, USA). Cultures were 
classified as having cobblestone, spindle or mesenchymal morphology.  
Immunofluorescence 
Standard techniques for immunofluorescence were used to stain for six epithelial, mesenchymal, 
and ovarian markers, Error! Reference source not found.. Cells were grown on coverslips, fixed with 
ice cold methanol prior to incubation with primary antibody. All cultures were assessed for antigen 
expression at passage 1. A panel of markers was used in the absence of a single specific epithelial 
ovarian marker. Cultures were deemed to be non-epithelial if they failed to demonstrate expression 
of either cytokeratin, MOC31 or EpCam and were discarded.  
Formal histopathology 
Formal cytological and histopathological examination of matched ascites and solid tumour 
specimens from every patient was performed and using standard techniques used to further 
characterise the cultures. This was performed by an independent expert pathologist blinded to the 
results of the antigen expression studies. Specimens were assigned to an ovarian histological 
subtype according to universal World Health Organisation criteria [19].  
When all characteristics were in keeping with epithelial ovarian origin, the samples were then used 
in subsequent experiments, at either passage 1 or 2. Cultures were discarded after passage 2. Where 
results were inconsistent with epithelial origin, cultures were discarded.  
Growth and Cell Proliferation assays 
A routine sulforhodamine B (SRB) assay was used to assess cytotoxicity and cell growth as previously 
described [20]. Briefly, cells were seeded at a density of 1000 cells/well and after adherence, treated 
with various concentrations of rucaparib (0, 0.1, 1, 10, 50, 100 μM) or cisplatin (0, 0.01, 0.03, 0.1, 
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0.3, 1, 3, 10 μM) for 10 days before fixation. For assessment of growth, cells were seeded, as above, 
then fixed at 24 hour intervals before staining and spectrophotometer assessment of cell density. 
The equation (t2 - t1)/3.32 x (log n2 - log n1) was used to caluclate doubling time, where t = time 
and n= cell density.  
Homologous recombination assay 
HR functional status was determined using a previously described method [16]. This assay quantifies 
Rad51, a crucial downstream protein involved in HR repair, which is relocalised within the nucleus in 
response to DNA damage to form distinct foci that can be visualized by immunofluorescent 
microscopy. Quantification of Rad51 in response to induction of DNA damage serves as a marker of 
HR function to distinguish between HR-proficient and HR-deficient cell lines. As part of the validation 
of this assay, a panel of cell lines with known HR function underwent Rad51 quantification in 
independent experiments [15, 16]. 
Cells were seeded onto uncoated glass cover slips and treated with 2 Gy ionising radiation and 
rucaparib at 10 µM concentration for 24 hours to induce double strand breaks (DSB) [15].  All 
experiments were performed alongside untreated controls with equivalent 0.1% DMSO. Cells were 
then fixed and rehydrated prior to staining with 1:100 mouse monoclonal anti-γH2AX (Upstate, 
Millipore Corp., USA) and 1:100 goat polyclonal anti-Rad51 (Calbiochem, EMD Biosciences, Inc.) 
antibodies with appropriate secondary fluorochrome conjugated antibodies, as previously described 
[16].  
Image J counting software [21, 22] was used to count γH2AX and Rad51 nuclear foci across three 
microscope fields for both treated (DNA damage induced) and control cells. The average number of 
foci per cell was expressed as percentage of untreated controls. Reliability, reproducibility, and 
validity of our data were confirmed by repeated tests across different fields, comparison of two 
counting methods (manual and software), and counting by two independent reviewer. Cells were 
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classed as HR competent if there was more than a 2 fold increase in Rad51 foci after DNA damage, 




Patient demographics for patients with solid and ascitic cultures are summarised in Table 2. In total 
PCO cultures from ascites with matched solid tumour were cultured from 25 patients. Collection was 
not restricted by histological subtype or collection at primary surgery only ensuring all patterns of 
heterogeneity were captured. Solid tumour was sampled from pelvic tumour only in 13 patients and 
in pelvic and intra abdominal deposits for the remaining 12 patients, giving an overall total of 68 
cultures. 
Intra-tumour heterogeneity of HR functional status 
When considered individually, of the 68 subcultures tested, 32 (47.1%) were HR competent and 36 
(52.9%) were HR defective, supplementary Table 2 for raw Rad51 data. 
HR function was homogeneous throughout all subcultures from an individual PCO patient in 13 of 
the 25 patients tested (52%). Of these 13 homogeneous PCO patients, five were universally HR 
defective and eight were universally HR competent.  Conversely there was heterogeneity of HR 
function between subcultures taken from the same patient in 12/25 (48%) cases.  
Combining results from all 25 patients but considering only a single biopsy, reflecting current 
diagnostic clinical practice, and comparing this to the HR status of the ascites, concordance rates for 
HR function were 19/25 (76%) cases. Concordance of HR function decreased to 3/12 (27%) when HR 
results were included from additional tumour sampling from two or more spatially distinct areas of 
solid tumour. Functional HR heterogeneity was not predictable based upon histological subtype, 
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immunohistochemistry of FFPE or immunofluorescent detected antigen expression. Intra-tumour 
heterogeneity of antigen expression is seen even within the same morphological group. 
Histological classification or characterisation of protein expression by 
immunohistochemistry or immunofluorescent microscopy has no clinical 
relevance in terms of response to therapy   
All subcultures were characterised in terms of morphology and classified as cobblestone, spindle cell 
or mesenchymal phenotype, Figure 1. In addition to morphology of actual cultures formal 
histopathological examination, supplemented with immunohistochemistry, of matched FFPE 
samples was also performed. The majority of the cohort (19/25, 76%) had high grade serous disease 
with a cobblestone monolayer appearance and almost all (23/35, 92%) had homogenous histology.   
Inter- and intra-tumour heterogeneity was seen between the expression of epithelial and ovarian 
markers using the immunoflourescent characterisation panel, 2. The majority of the tumours 
showed expression of epithelial as well as mesenchymal markers using both techniques. Vimentin 
expression was universal throughout all subcultures.  
PCO samples taken from nine patients showed completely homogeneous staining patterns between 
all subcultures from the same patient with no difference in expression of any markers between 
ascitic and solid subcultures for epithelial, mesenchymal or ovarian markers.  
However for 16 patients there was non concordance between at least one of the markers. With the 
exception of vimentin, concordance rates decreased as the number of samples analysed for each 
patient was increased from two (ascites and one solid sample) to three (ascites and two paired solid 
samples), Table 3. 
Heterogeneity of expression was seen universally amongst all antigen groups (epithelial and 
ovarian). This heterogeneity was not reflected in the histological classification of the tumours with 
only 2/16 (12.5%) patients with heterogeneous antigen expression being classified as having mixed 
histological subtypes on formal pathology, κ = -0.560 (95%CI -0.780 to -0.340).  
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Antigen expression with time – supplemetray table 2 
 
Ex vivo growth rate is highly variable and heterogeneous between and 
within PCOs 
The median doubling time for all cultures was 126 hours, range 55 - 303. There was no significant 
difference between the median doubling times of HR competent (126 hours, 55 - 303) and HR 
defective tumours (128 hours, 81 - 233), (p=0.2543). The median doubling time for solid cultures 
(120 hours, 82 – 279) was lower than for ascitic cultures (159 hours, 55 - 303), (p=0.0142). The inter- 
and intra-tumour doubling times were highly variable. When comparing all subcultures from each 
PCO patient, there was no significant difference in the doubling times between PCO patients 
(ANOVA, p=0.1425) but there was a significant difference between the SD of each PCO group of 
subcultures (Brown-Forsythe, p = 0.0098) indicating that intra-tumour heterogeneity is greater than 
inter-tumour heterogeneity in terms of growth, Figure 2.  
Sensitivity to cisplatin and rucaparib correlates with HR functional status 
Sensitivity to rucaparib and cisplatin was assessed for 59/68 subcultures generated. There was 
84.7% concordance between HR status and rucaparib sensitivity and 75.5% concordance between 
HR status and platinum sensitivity. When subcultures are grouped together according to HR 
function, HR defective cultures were sensitive to both cisplatin and rucaparib with mean GI50 of 4.02 
µM and 9.73 µM respectively; compared to HR competent cultures, with mean GI50 of >10 µM and 







In this study we add to current evidence of inter-tumourol heterogeneity in ovarian cancer in terms 
of antigen expression and proliferation rate, and DNA repair HR function from ascites. Additionally, 
we provide new evidence that a large proportion of ovarian cancer patients have intra-tumoural 
heterogeneity in terms of HR function with approximately 50% of tumours demonstrating intra-
tumoural heterogeneity in this feature. The correlation of HR status with cytotoxic sensitivity to 
cisplatin and PARP inhibitors is important as it demonstrates the relevance of the approach of 
functional analysis. This heterogeneity of the function biomarker HR is not related to or predictable 
using histological subtype.  
Bashashati et al have recently described extensive intratumoural mutational diversity in a small 
panel of high grade serous cancers with TP53 being the only somatic mutation present in all samples 
and only 51.5% concordance in the presence of other driver mutations across all samples from each 
patient [13].  This builds upon previous work by Khalique et al who suggested that ovarian cancer 
develops by a non linear clonal evolutionary process [23]. Taken together these findings suggest a 
model in which early divergence gives rise to clones with different driver mutation phenotypes, the 
only common feature being mutation of TP53.  Given that dysfunction of DNA damage repair 
pathways are also key driver events [24] it is perhaps unsurprising therefore to see variable DNA 
repair status in different areas of the same tumour representing these different, early divergent, 
clones. 
By correlating the results of functional analysis of the HR pathway with ex vivo response to 
chemotherapy for each subculture studied we suggest that this divergence and subsequent 
heterogeneity has an important implication for clinical practice both in terms of partly explaining the 
variable response to chemotherapy but also in determining the limited benefit of relying on the 
results of single biopsies to stratify treatment. 
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The main limitation of this work is the relatively small number of patients included (25 patients 
contributing 68 successful primary cultures). The impact of intra-tumoural functional heterogeneity 
upon PFS and OS is difficult to interpret in this small cohort and is additionally complicated by the 
many variable clinical factors, in particular the timing and end result of cytoreductive surgery. In 
order to correct analyses for the patient and histological variances the sample size required is large 
and may in fact require a multi-centre approach. This study does raise the possibility that tumours 
demonstrating significant intra-tumoural heterogeneity at presentation may be more likely to 
demonstrate resistance to chemotherapy.  The finding of heterogeneity in tumours even following 
neoadjuvant chemotherapy (commonly 3-4 cycles of carboplatin with or without taxane), 
demonstrates that the selection pressure of chemotherapy may be less than previously thought and 
reinforces the importance of thorough sampling in every tumour at surgery irrespective of preceding 
therapy .  
We have previously demonstrated a very strong correlation between HR status and ex vivo 
sensitivity to the PARP inhibitor rucaparib using cells cultured from just one compartment, namely 
ascites [16] with responses seen in approximately 50% of cases [3]. In clinical practice however, 
response rates to olaparib in non germline BRCA 1 and 2 patients are only 24% [25]. This may be a 
result of underlying heterogeneity at presentation and subsequent clonal selection pressure as a 
result of initial chemotherapy. 
The demonstration in this study that the results of predictive biomarkers will be affected by intra 
tumour heterogeneity has ramifications for future translational research and biomarker directed 
therapy. It is crucial that future studies include multiple biopsies to allow assessment of intra tumour 
heterogeneity and that protocols which require sequential biopsies taken before and after 
treatment attempt to collect these biopsies from the same tumour site to minimise the risk of 
selecting non paired clones. 
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Further work is required to extend this work. In particular correlation of heterogeneity with disease 
location (intra peritoneal versus extra peritoneal) would provide insight into the biology of the 
metastatic process in ovarian cancer. 
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 Legends to figures 
Figure 1: Brightfield microscopy (x10) demonstrating cobblestone (PCO 174 – ascites), 
mesenchymal (PCO 179 – ascites) and spindle cell morphology (PCO 226 – ovary). 
 
Figure 2: representative images demonstrating intra tumour heterogeneity from a single patient. 
(A) Cultures were generated from 6 spatially distinct deposits. (B) expression of 
immunofluorescent markers varied between early passage cultures. (C) rucaparib sensitivity 
assays revealed two distinct phenotypes. These correlated with HR status.  
 
Figure 3 Growth rate of patient samples shows high intra and inter tumour variability. The 
doubling time of individual cultures was estimated and is expressed as median (range) for each set 
of patient samples 
 
Figure 4 Sensitivity to rucaparib and cisplatin by HR function. A total of 59 subcultures were 
generated and treated with (A) rucaparib or (B) cisplatin. Those cultures deemed HR defective had 










Marker Description Concentration Company 
Pancytokeratin PCO samples were classified to be 
epithelial in origin if more than 95% 
of cells stained with mouse 
monoclonal anti-pancytokeratin 
FITC–conjugated antibody. Clone 
C11 





Epithelial origin was confirmed 
with positive staining for 1:100 
mouse monoclonal anti-CD326 
(EpCAM) Alexafluor® 488–
conjugated antibody. Clone 9C4 
1:100 Biolegend, USA 
Cancer Antigen 
125 (CA125) 
CA125 is a tumour marker 
expressed in approximately 80% of 
epithelial ovarian cancers [29]. 
Expression was assessed using 
mouse monoclonal anti-CA125 
antibody and Alexafluor® 546 goat 













glycoprotein 2 (EGP-2, also known 
as ESA, GA733-2, KSA) is present on 
most normal and malignant 
epithelia [30] enabling 
discrimination from mesothelial 
derived tumours.  Expression was 
assessed using mouse monoclonal 
anti-MOC-31 antibody and 
Alexaflour® 596 goat anti-mouse 









Vimentin Marker commonly used to detect 
epithelial-mesenchymal transition 
(EMT). Expression was assessed 
using rabbit monoclonal anti-
vimentin antibody, clone EPR3776 












Table 2 – Summary of patient demographics  
 
Demographic Median (range) / n (%) 
Patient age (years) 63 (43 - 83) 








Serum CA125 at presentation (U/l) 600 (57 – 9740) 
Histology 





































Two sample concordance1 
(%) (n=25) 
Three sample concordance2 
(%) (n=12) 
CK 92 58 
CA125 68 42 
EpCam 56 36 
MOC31 65 36 
Vimentin 100 100 
   
HR status 76 27 
 
 
1 concordance between ascitic sample and single paired solid sample 
2 concordance between ascitic sample and two paired solid samples 
 
 
 
 
